PARP1/2 ja PARG , SMAD

https://www.ncbi.nlm.nih.gov/pubmed/19273151

Front Biosci (Landmark Ed). 2009 Jan 1;14:1619-26.

Poly (ADP-ribose) glycohydrolase (PARG) and its therapeutic potential.

Min W¹, Wang ZQ.  Abstract

Poly (ADP-ribose) glycohydrolase (PARG) is a catabolic enzyme that cleaves ADP-ribose polymers synthesized by members of the poly (ADP-ribose) polymerase (PARP) family of enzymes. The growing evidence supports the importance of a tight control of poly (ADP-ribose) metabolism by the two major enzymes, PARP-1 and PARG. Recent studies have advanced the understanding of PARPs' and PARG's functions in various cellular and physiological processes. In the last 10 years, homeostasis of poly (ADP-ribosyl)ation has been a target of pharmaceutical interventions for various pathologies. Although the polymer synthesizing enzyme PARP-1 has been well studied, the function of PARG remains largely unknown. However, a great effort has been made in recent years to delineate biological functions of PARG and to explore the therapeutical potentials of PARG inhibition in pathophysiological conditions such as inflammation, ischemia, stroke, and cancer chemotherapy.PMID: 19273151 [Indexed for MEDLINE]

 SMAD, PARP ja PARG :(Picture in the link)

Fine-Tuning of Smad Protein Function by Poly(ADP-Ribose) Polymerases and Poly(ADP-Ribose) Glycohydrolase during Transforming Growth Factor β Signaling

• Markus Dahl ,
  
• Varun Maturi ,
• Peter Lönn ,
• Panagiotis Papoutsoglou ,
• Agata Zieba,
• Michael Vanlandewijck,
• Lars P. van der Heide,
• Yukihide Watanabe,
• Ola Söderberg,
• Michael O. Hottiger,
• Carl-Henrik Heldin,
• Aristidis Moustakas

• 
  
• 
  
• 
  

• Published: August 18, 2014
• https://doi.org/10.1371/journal.pone.0103651